{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:38:40Z","timestamp":1774946320927,"version":"3.50.1"},"reference-count":25,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinical Cooperative Pilot: Project of Traditional Chinese and Western Medicine for Major Diseases","award":["Administration of State Administration of Traditional Chinese Medicine [2018], no. 3"],"award-info":[{"award-number":["Administration of State Administration of Traditional Chinese Medicine [2018], no. 3"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2018YFC1311505"],"award-info":[{"award-number":["2018YFC1311505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gansu Provincial Clinical Research Center for Cardiovascular Diseases","award":["18JR2FA005"],"award-info":[{"award-number":["18JR2FA005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Residual inflammation and persistent lipid abnormalities substantially increase the risk of adverse clinical outcomes in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PPCI). Although proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes, the efficacy, safety, and prognosis of these inhibitors when administered as a single dose after PPCI in real-world practice remain unclear. Method: A retrospective study of patients with acute ST-segment elevation myocardial infarction (STEMI) admitted between May 2023 and May 2024. Patients were assigned to an alirocumab group or a conventional treatment group based on whether a single dose of alirocumab was administered within 6 hours of PPCI. Baseline differences between groups were balanced using 1:1 propensity score matching (PSM). The occurrence of major adverse cardiovascular events (MACEs) at 12 months post-procedure was applied as the primary endpoint. Secondary endpoints included lipid profiles, inflammatory markers, cardiac function, quality-of-life changes, and safety outcomes. Results: A non-significant downward trend in the incidence of MACEs at 12 months post-PPCI was observed in the alirocumab group compared with the conventional treatment group (log-rank p = 0.242). A single dose of alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) at 1 month (p = 0.011) and attenuated inflammation markers at 24 hours postoperatively. At 12 months, the alirocumab group showed improved cardiac function with significantly reduced left ventricular end-systolic volume (LVESV, p = 0.009) and modest but statistically significant improvement in quality of life (p = 0.012), primarily driven by enhanced physical activity (p &lt; 0.001), alongside reduced insecurity (p &lt; 0.001). No increased incidence of adverse events was observed (p &gt; 0.05). Conclusions: This study demonstrated that a single dose of alirocumab in STEMI patients undergoing PPCI was associated with significant improvement in LDL-C levels, attenuation of early postoperative inflammation, and a favorable trend toward improved cardiac function and quality of life, while maintaining an acceptable safety profile.<\/jats:p>","DOI":"10.31083\/rcm47437","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:28:46Z","timestamp":1774942126000},"source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Single-Dose Alirocumab on Efficacy and Safety After Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Single-Center Retrospective Real-World Study"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5616-9014","authenticated-orcid":true,"given":"Pei","family":"Wang","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, 730000 Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6687-7014","authenticated-orcid":true,"given":"Haixia","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, 730000 Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6464","authenticated-orcid":true,"given":"Dongdong","family":"Yan","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, 730000 Lanzhou, Gansu, China"},{"name":"Department of Cardiology, The First Hospital of Lanzhou University, 730000 Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1304-9735","authenticated-orcid":true,"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, 730000 Lanzhou, Gansu, China"},{"name":"Department of Cardiology, The First Hospital of Lanzhou University, 730000 Lanzhou, Gansu, China"},{"name":"Gansu Provincial Clinical Research Center for Cardiovascular Diseases, 730000 Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020; 76: 2982\u20133021.","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2025; 85: 2135\u20132237.","DOI":"10.1016\/j.jacc.2024.11.009"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Nejabat M, Hadizadeh F, Almahmeed W, Sahebkar A. Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases. Drug Discovery Today. 2025; 30: 104316.","DOI":"10.1016\/j.drudis.2025.104316"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Liu G, Yu X, Cui C, Li X, Wang T, Palade PT, et al. The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism. Acta Physiologica (Oxford, England). 2025; 241: e14272.","DOI":"10.1111\/apha.14272"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022; 146: 1109\u20131119.","DOI":"10.1161\/CIRCULATIONAHA.122.061620"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, et al. Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial. Journal of the American Heart Association. 2023; 12: e029216.","DOI":"10.1161\/JAHA.122.029216"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Giordano S, Ielapi J, Salerno N, Cersosimo A, Lucchino A, Laschera A, et al. Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome. Reviews in Cardiovascular Medicine. 2024; 25: 374.","DOI":"10.31083\/j.rcm2510374"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). Journal of the American College of Cardiology. 2019; 74: 2452\u20132462.","DOI":"10.1016\/j.jacc.2019.08.010"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mehta SR, Pare G, Lonn EM, Jolly SS, Natarajan MK, Pinilla-Echeverri N, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2022; 18: e888\u2013e896.","DOI":"10.4244\/EIJ-D-22-00735"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ye X, Zhang S, Zhong X, Li M, Liu M, Zhuang X, et al. Real-World Assessment of the Association Between PCSK9i Adherence and LDL Reduction and Variability in a Chinese Clinical Practice. Clinical Epidemiology. 2025; 17: 537\u2013546.","DOI":"10.2147\/CLEP.S507761"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. International Journal of Surgery (London, England). 2014; 12: 1495\u20131499.","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Watson R, Wang W, Ski CF, Thompson DR. The Chinese version of the Myocardial Infarction Dimensional Assessment Scale (MIDAS): Mokken scaling. Health and Quality of Life Outcomes. 2012; 10: 2.","DOI":"10.1186\/1477-7525-10-2"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023; 44: 3720\u20133826.","DOI":"10.1093\/ehjacc\/zuad107"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Krychtiuk KA, Claeys MJ, Gencer B, Mach F. In-hospital initiation of PCSK9 inhibitors in ACS: pros and cons. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2023; 19: e283\u2013e285.","DOI":"10.4244\/EIJ-E-23-00014"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, et al. Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial. Circulation. 2020; 142: 419\u2013421.","DOI":"10.1161\/CIRCULATIONAHA.120.046320"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Yifan D, Yue M, Yubin Z, Jiapei G, Xun S, Shenghu H, et al. The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: A systematic review and meta-analysis. International Journal of Cardiology. 2024; 399: 131775.","DOI":"10.1016\/j.ijcard.2024.131775"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Li H, Wei Y, Yang Z, Zhang S, Xu X, Shuai M, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study. American Journal of Cardiovascular Drugs: Drugs, Devices, and other Interventions. 2020; 20: 489\u2013503.","DOI":"10.1007\/s40256-020-00394-1"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM, Pirro M, Banach M, Awan Z, et al. PCSK9 and inflammation: a review of experimental and clinical evidence. European Heart Journal. Cardiovascular Pharmacotherapy. 2019; 5: 237\u2013245.","DOI":"10.1093\/ehjcvp\/pvz022"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Cao YX, Li S, Liu HH, Li JJ. Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2018; 8: e022348.","DOI":"10.1136\/bmjopen-2018-022348"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Bulluck H, Carberry J, Carrick D, McEntegart M, Petrie MC, Eteiba H, et al. Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segment-Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis. Circulation. Cardiovascular Imaging. 2020; 13: e009937.","DOI":"10.1161\/CIRCIMAGING.119.009937"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Tromp J, Lam CSP, Alemayehu W, de Filippi CR, Melenovsk\u00fd V, Sliwa K, et al. Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial. European Journal of Heart Failure. 2024; 26: 2231\u20132239.","DOI":"10.1002\/ejhf.3397"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Falc\u00e3o-Pires I, Ferreira AF, Trindade F, Bertrand L, Ciccarelli M, Visco V, et al. Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function. European Journal of Heart Failure. 2024; 26: 1454\u20131479.","DOI":"10.1002\/ejhf.3264"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ziogos E, Harb T, Valenta I, Vavuranakis MA, Foran PL, Williams MS, et al. Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial. JACC. Basic to Translational Science. 2025; 10: 709\u2013720.","DOI":"10.1016\/j.jacbts.2025.03.010"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Seijas-Amigo J, Mauriz-Montero MJ, Suarez-Artime P, Gayoso-Rey M, Reyes-Sant\u00edas F, Estany-Gestal A, et al. Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study. Diseases (Basel, Switzerland). 2024; 12: 244.","DOI":"10.3390\/diseases12100244"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cesaro A, Gragnano F, Fimiani F, Moscarella E, Diana V, Pariggiano I, et al. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. European Journal of Preventive Cardiology. 2020; 27: 556\u2013558.","DOI":"10.1177\/2047487319839179"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/3\/10.31083\/RCM47437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:30:00Z","timestamp":1774942200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/3\/10.31083\/RCM47437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02346-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm47437","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"47437"}}